Denali therapeutics announces positive interim data from phase 1/2 study with etv:ids (dnl310) in patients with the lysosomal storage disease hunter syndrome (mps ii)

South san francisco, calif., july 25, 2021 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for neurodegenerative diseases, today announced additional positive interim data from a phase 1/2 study evaluating etv:ids (dnl310), an investigational brain-penetrant enzyme replacement therapy intended to treat both central nervous system (cns) and peripheral manifestations of hunter syndrome (mps ii). the interim results being presented today at mps 2021, the 16th international symposium on mps and related diseases, include safety data up to weeks 43 and 25 from cohorts a and b, respectively, 6-month biomarker data from cohort a and up to 3-month biomarker data from cohort b. denali management will host a webinar today for analysts and investors beginning at approximately 11:30 a.m. eastern time.
DNLI Ratings Summary
DNLI Quant Ranking